Associations Between HIV and Severe Mpox in an Atlanta Cohort
- 24 November 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 229 (Supplement) , S234-S242
Abstract
Background: In the Southeastern United States, the 2022 mpox outbreak disproportionately impacted people who are black and people with HIV (PWH). Methods: We analyzed a cohort of 395 individuals diagnosed with mpox across 3 health care systems in Atlanta, Georgia between 1 June 2022 and 7 October 2022. We present demographic and clinical characteristics and use multivariable logistic regression analyses to evaluate the association between HIV status and severe mpox (per the US Centers for Disease Control and Prevention definition) and, among PWH, the associations between CD4+ T-cell count and HIV load with severe mpox. Results: Of 395 people diagnosed with mpox, 384 (97.2%) were cisgender men, 335 (84.8%) identified as black, and 324 (82.0%) were PWH. Of 257 PWH with a known HIV load, 90 (35.0%) had > 200 copies/mL. Severe mpox occurred in 77 (19.5%) individuals and there was 1 (0.3%) death. Tecovirimat was prescribed to 112 (28.4%) people, including 56 (72.7%) people with severe mpox. In the multivariable analysis of the total population, PWH had 2.52 times higher odds of severe mpox (95% confidence interval [CI], 1.01–6.27) compared with people without HIV. In the multivariable analysis of PWH, individuals with HIV load > 200 copies/mL had 2.10 (95% CI, 1.00–4.39) times higher odds of severe mpox than PWH who were virologically suppressed. Lower CD4+ T-cell count showed a significant univariate association with severe mpox but was not found to be significantly associated with severe mpox in multivariable analysis. Conclusions: PWH with nonsuppressed HIV loads had more mpox complications, hospitalizations, and protracted disease courses than people without HIV or PWH with suppressed viral loads. PWH with nonsuppressed HIV loads who are diagnosed with mpox warrant particularly aggressive monitoring and treatment.Keywords
This publication has 14 references indexed in Scilit:
- Human Mpox in People Living with HIV: Epidemiologic and Clinical Perspectives from NigeriaAIDS Research and Human Retroviruses, 2023
- Clinical Features, Antiviral Treatment, and Patient Outcomes: A Systematic Review and Comparative Analysis of the Previous and the 2022 Mpox OutbreaksThe Journal of Infectious Diseases, 2023
- MonkeypoxThe Lancet, 2022
- Monkeypox: disease epidemiology, host immunity and clinical interventionsNature Reviews Immunology, 2022
- Monkeypox: A Contemporary Review for Healthcare ProfessionalsOpen Forum Infectious Diseases, 2022
- Clinical Course and Outcome of Human Monkeypox in NigeriaClinical Infectious Diseases, 2020
- Natural killer cells in HIV-1 infection and therapyAIDS, 2017
- Anatomically Restricted Synergistic Antiviral Activities of Innate and Adaptive Immune Cells in the SkinCell Host & Microbe, 2013
- B cells in HIV infection and diseaseNature Reviews Immunology, 2009
- HIV-1 Viremia Prevents the Establishment of Interleukin 2–producing HIV-specific Memory CD4+ T Cells Endowed with Proliferative CapacityJournal of Experimental Medicine, 2003